Dr. Idos on Remaining Questions With Multiplex Panel Testing

Gregory E. Idos, MD
Published: Tuesday, Sep 27, 2016



Gregory E. Idos, MD, assistant professor of Clinical Medicine, Department of Surgery, Division of Colorectal Surgery, Keck School of Medicine of University of Southern California, sheds light on the cost effectiveness and other questions surrounding multiplex panel testing.

Currently, researchers are exploring the overall utility of how multiplex panel tests could potentially affect surgical management and chemotherapy prevention, Idos explains.

Regarding cost, using the gene-by-gene approach has been found to be more expensive than multiplex panel testing, he adds. Over the last few years, it has also been found that the cost of sequencing has gone down.


Gregory E. Idos, MD, assistant professor of Clinical Medicine, Department of Surgery, Division of Colorectal Surgery, Keck School of Medicine of University of Southern California, sheds light on the cost effectiveness and other questions surrounding multiplex panel testing.

Currently, researchers are exploring the overall utility of how multiplex panel tests could potentially affect surgical management and chemotherapy prevention, Idos explains.

Regarding cost, using the gene-by-gene approach has been found to be more expensive than multiplex panel testing, he adds. Over the last few years, it has also been found that the cost of sequencing has gone down.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x